Effect of 125I seed implantation combined with chemotherapy in treatment of liver metastasis of advanced colorectal cancer / 中国介入影像与治疗学

ABSTRACT

Objective: To observe the clinical effect and safety of 125I seed implantation combined with chemotherapy in treatment of advanced colorectal cancer with liver metastasis. Methods: Totally 27 cases of advanced colorectal cancer with 60 liver metastasis were enrolled. 125I seed implantation was performed, followed by second-line chemotherapy. The clinical effect, safety and prognosis of the above treatments were observed. Results: Totally 1 995 125I seeds were successfully implanted into 60 liver metastasis([33.41±24.79]seeds in each lesion), and the dose distribution was uniform. Postoperative adverse reactions were mild and recovered after symptomatic treatment. There was no significant difference of liver function before and 1 week after 125I seed implantation. Six patients were treated with oxaliplatin combined regimen and 21 with irinotecan combined regimen 1 week after 125I seed implantation. At the end of 3 and 6 cycles of chemotherapy, the lesion diameter and carcinoembryonic antigen (CEA) level significantly reduced compared with those before implantation (both P< 0.001). The median progression-free survival (PFS) and median overall lifetime (OS) was 8.1 months and 14.6 months, respectively. Conclusion: 125I seed implantation combined with second-line chemotherapy is safe and effective in near future for treating advanced colorectal cancer patients with liver metastasis.